Intellia Therapeutics (NTLA) Q4 2025 earnings summary

Executive summary

• Achieved rapid enrollment in key phase 3 trials for ATTR amyloidosis (MAGNITUDE, MAGNITUDE-2) and hereditary angioedema (HAELO), with MAGNITUDE-2 resuming after FDA hold was lifted following protocol amendments.

• Lonvo-z and Nex-z, both one-time gene-editing therapies, continue to show durable efficacy with no waning of effect up to three years in trials.

• Strong patient and physician interest in lonvo-z, with market research indicating high likelihood of adoption if approved.

• Commercial readiness efforts for lonvo-z are well underway, including field team expansion, payer engagement, and launch strategy development.

• Addressed clinical holds on nex-z Phase 3 trials, with MAGNITUDE-2 hold lifted and enrollment resuming; MAGNITUDE trial for ATTR-CM remains on hold pending FDA alignment.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $605.1 million as of December 31, 2025, down from $861.7 million a year prior.

• Collaboration revenue for Q4 2025 was $23 million, up from $12.9 million in Q4 2024, driven by contract terminations and increased reimbursements.

• R&D expenses decreased to $88.7 million in Q4 2025 from $116.9 million in Q4 2024, mainly due to lower employee and material costs.

• Net loss for Q4 2025 was $95.8 million, a significant improvement from $128.9 million in the prior-year quarter; full-year net loss was $412.7 million versus $519.0 million in 2024.

• Operating loss for Q4 2025 was $98.7 million, compared to $136.4 million in Q4 2024.

Outlook and guidance

• Cash runway expected to extend into the second half of 2027, covering key milestones including MAGNITUDE-2 completion and lonvo-z launch.

• Top-line data for lonvo-z in HAE expected mid-2026, with BLA submission planned for the second half of 2026 and U.S. launch targeted for first half of 2027.

• MAGNITUDE-2 enrollment expected to complete in the second half of 2026; ongoing FDA engagement for MAGNITUDE trial.

• Commercial launch preparations for lonvo-z continue, with focus on sales, reimbursement, and distribution infrastructure.